Table 1: Background of enrolled patients.
Total | |
Number of patients received iBCG therapy | 555 cases |
Male/Female ratio | 438/117 cases |
Mean age ± SD (years) | 72 ± 10 |
T stage of bladder cancer (Tis/Ta/T1/T2) | 158/209/158/30 cases |
Cellular atypism (G1/G2/G3) | 146/283/126 cases |
iBCG: intravesical Bacillus Calmette-Guerin; Tis: carcinoma in situ; Ta: noninvasive papillary cancer; T1: invasion to submucosa; T2: invasion to muscle layer; G1: low-grade; G2: lowgrade and high-grade; G3: high-grade cancer.